The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1bn, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, and ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

The UK drugmaker AstraZeneca has agreed to acquire Belgian cell therapy developer EsoBiotec for up to $1bn to enhance its cancer treatment capabilities. Read more.